vs
HAEMONETICS CORP（HAE）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
HAEMONETICS CORP的季度营收约是ROGERS CORP的1.7倍（$339.0M vs $200.5M），HAEMONETICS CORP净利率更高（13.2% vs 2.2%，领先11.0%），ROGERS CORP同比增速更快（5.2% vs -2.7%），HAEMONETICS CORP自由现金流更多（$87.2M vs $1.1M），过去两年HAEMONETICS CORP的营收复合增速更高（0.4% vs -3.3%）
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
HAE vs ROG — 直观对比
营收规模更大
HAE
是对方的1.7倍
$200.5M
营收增速更快
ROG
高出8.0%
-2.7%
净利率更高
HAE
高出11.0%
2.2%
自由现金流更多
HAE
多$86.1M
$1.1M
两年增速更快
HAE
近两年复合增速
-3.3%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $339.0M | $200.5M |
| 净利润 | $44.7M | $4.5M |
| 毛利率 | 59.7% | 32.2% |
| 营业利润率 | 19.9% | — |
| 净利率 | 13.2% | 2.2% |
| 营收同比 | -2.7% | 5.2% |
| 净利润同比 | 19.3% | 421.4% |
| 每股收益（稀释后） | $0.95 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HAEROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $339.0M | $201.5M | ||
| Q3 25 | $327.3M | $216.0M | ||
| Q2 25 | $321.4M | $202.8M | ||
| Q1 25 | $330.6M | $190.5M | ||
| Q4 24 | $348.5M | $192.2M | ||
| Q3 24 | $345.5M | $210.3M | ||
| Q2 24 | $336.2M | $214.2M |
净利润HAEROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $44.7M | $4.6M | ||
| Q3 25 | $38.7M | $8.6M | ||
| Q2 25 | $34.0M | $-73.6M | ||
| Q1 25 | $58.0M | $-1.4M | ||
| Q4 24 | $37.5M | $-500.0K | ||
| Q3 24 | $33.8M | $10.7M | ||
| Q2 24 | $38.4M | $8.1M |
毛利率HAEROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 59.7% | 31.5% | ||
| Q3 25 | 59.5% | 33.5% | ||
| Q2 25 | 59.8% | 31.6% | ||
| Q1 25 | 58.4% | 29.9% | ||
| Q4 24 | 55.5% | 32.1% | ||
| Q3 24 | 54.2% | 35.2% | ||
| Q2 24 | 52.0% | 34.1% |
营业利润率HAEROG
| Q1 26 | — | — | ||
| Q4 25 | 19.9% | 3.5% | ||
| Q3 25 | 17.9% | 7.3% | ||
| Q2 25 | 16.8% | -33.3% | ||
| Q1 25 | 21.6% | -0.2% | ||
| Q4 24 | 16.9% | -6.6% | ||
| Q3 24 | 15.0% | 6.9% | ||
| Q2 24 | 11.8% | 5.3% |
净利率HAEROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 13.2% | 2.3% | ||
| Q3 25 | 11.8% | 4.0% | ||
| Q2 25 | 10.6% | -36.3% | ||
| Q1 25 | 17.5% | -0.7% | ||
| Q4 24 | 10.8% | -0.3% | ||
| Q3 24 | 9.8% | 5.1% | ||
| Q2 24 | 11.4% | 3.8% |
每股收益（稀释后）HAEROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.95 | $0.20 | ||
| Q3 25 | $0.81 | $0.48 | ||
| Q2 25 | $0.70 | $-4.00 | ||
| Q1 25 | $1.17 | $-0.08 | ||
| Q4 24 | $0.74 | $-0.04 | ||
| Q3 24 | $0.66 | $0.58 | ||
| Q2 24 | $0.74 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $363.4M | $195.8M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $911.5M | $1.2B |
| 总资产 | $2.5B | $1.4B |
| 负债/权益比越低杠杆越低 | 1.34× | — |
8季度趋势，按日历期对齐
现金及短期投资HAEROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $363.4M | $197.0M | ||
| Q3 25 | $296.4M | $167.8M | ||
| Q2 25 | $292.9M | $157.2M | ||
| Q1 25 | $306.8M | $175.6M | ||
| Q4 24 | $320.8M | $159.8M | ||
| Q3 24 | $299.3M | $146.4M | ||
| Q2 24 | $344.4M | $119.9M |
总债务HAEROG
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益HAEROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $911.5M | $1.2B | ||
| Q3 25 | $849.2M | $1.2B | ||
| Q2 25 | $882.3M | $1.2B | ||
| Q1 25 | $820.8M | $1.3B | ||
| Q4 24 | $906.9M | $1.3B | ||
| Q3 24 | $878.9M | $1.3B | ||
| Q2 24 | $905.4M | $1.3B |
总资产HAEROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.5B | $1.4B | ||
| Q3 25 | $2.4B | $1.4B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.5B | $1.5B | ||
| Q4 24 | $2.5B | $1.5B | ||
| Q3 24 | $2.5B | $1.5B | ||
| Q2 24 | $2.5B | $1.5B |
负债/权益比HAEROG
| Q1 26 | — | — | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $93.6M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $87.2M | $1.1M |
| 自由现金流率自由现金流/营收 | 25.7% | 0.5% |
| 资本支出强度资本支出/营收 | 1.9% | 2.3% |
| 现金转化率经营现金流/净利润 | 2.09× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $308.1M | $70.1M |
8季度趋势，按日历期对齐
经营现金流HAEROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $93.6M | $46.9M | ||
| Q3 25 | $111.3M | $28.9M | ||
| Q2 25 | $17.4M | $13.7M | ||
| Q1 25 | $116.6M | $11.7M | ||
| Q4 24 | $43.8M | $33.7M | ||
| Q3 24 | $48.8M | $42.4M | ||
| Q2 24 | $-27.4M | $22.9M |
自由现金流HAEROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $87.2M | $42.2M | ||
| Q3 25 | $106.3M | $21.2M | ||
| Q2 25 | $13.6M | $5.6M | ||
| Q1 25 | $100.9M | $2.1M | ||
| Q4 24 | $35.2M | $18.3M | ||
| Q3 24 | $39.4M | $25.2M | ||
| Q2 24 | $-33.1M | $8.8M |
自由现金流率HAEROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 25.7% | 20.9% | ||
| Q3 25 | 32.5% | 9.8% | ||
| Q2 25 | 4.2% | 2.8% | ||
| Q1 25 | 30.5% | 1.1% | ||
| Q4 24 | 10.1% | 9.5% | ||
| Q3 24 | 11.4% | 12.0% | ||
| Q2 24 | -9.8% | 4.1% |
资本支出强度HAEROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.9% | 2.3% | ||
| Q3 25 | 1.5% | 3.6% | ||
| Q2 25 | 1.2% | 4.0% | ||
| Q1 25 | 4.7% | 5.0% | ||
| Q4 24 | 2.5% | 8.0% | ||
| Q3 24 | 2.7% | 8.2% | ||
| Q2 24 | 1.7% | 6.6% |
现金转化率HAEROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 2.09× | 10.20× | ||
| Q3 25 | 2.88× | 3.36× | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | 3.96× | ||
| Q2 24 | -0.71× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
ROG
暂无分部数据
